These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

412 related items for PubMed ID: 30188931

  • 1. Evaluation of potential effects of Plastin 3 overexpression and low-dose SMN-antisense oligonucleotides on putative biomarkers in spinal muscular atrophy mice.
    Strathmann EA, Peters M, Hosseinibarkooie S, Rigo FW, Bennett CF, Zaworski PG, Chen KS, Nothnagel M, Wirth B.
    PLoS One; 2018; 13(9):e0203398. PubMed ID: 30188931
    [Abstract] [Full Text] [Related]

  • 2. The Power of Human Protective Modifiers: PLS3 and CORO1C Unravel Impaired Endocytosis in Spinal Muscular Atrophy and Rescue SMA Phenotype.
    Hosseinibarkooie S, Peters M, Torres-Benito L, Rastetter RH, Hupperich K, Hoffmann A, Mendoza-Ferreira N, Kaczmarek A, Janzen E, Milbradt J, Lamkemeyer T, Rigo F, Bennett CF, Guschlbauer C, Büschges A, Hammerschmidt M, Riessland M, Kye MJ, Clemen CS, Wirth B.
    Am J Hum Genet; 2016 Sep 01; 99(3):647-665. PubMed ID: 27499521
    [Abstract] [Full Text] [Related]

  • 3. Plastin 3 Expression Does Not Modify Spinal Muscular Atrophy Severity in the ∆7 SMA Mouse.
    McGovern VL, Massoni-Laporte A, Wang X, Le TT, Le HT, Beattie CE, Rich MM, Burghes AH.
    PLoS One; 2015 Sep 01; 10(7):e0132364. PubMed ID: 26134627
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L, Schneider S, Rombo R, Ling KK, Grysko V, Upadhyay A, Kononenko NL, Rigo F, Bennett CF, Wirth B.
    Am J Hum Genet; 2019 Jul 03; 105(1):221-230. PubMed ID: 31230718
    [Abstract] [Full Text] [Related]

  • 7. Normalization of Patient-Identified Plasma Biomarkers in SMNΔ7 Mice following Postnatal SMN Restoration.
    Arnold WD, Duque S, Iyer CC, Zaworski P, McGovern VL, Taylor SJ, von Herrmann KM, Kobayashi DT, Chen KS, Kolb SJ, Paushkin SV, Burghes AH.
    PLoS One; 2016 Jul 03; 11(12):e0167077. PubMed ID: 27907033
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Spinal muscular atrophy: antisense oligonucleotide therapy opens the door to an integrated therapeutic landscape.
    Wood MJA, Talbot K, Bowerman M.
    Hum Mol Genet; 2017 Oct 01; 26(R2):R151-R159. PubMed ID: 28977438
    [Abstract] [Full Text] [Related]

  • 11. Genetic modifiers ameliorate endocytic and neuromuscular defects in a model of spinal muscular atrophy.
    Walsh MB, Janzen E, Wingrove E, Hosseinibarkooie S, Muela NR, Davidow L, Dimitriadi M, Norabuena EM, Rubin LL, Wirth B, Hart AC.
    BMC Biol; 2020 Sep 16; 18(1):127. PubMed ID: 32938453
    [Abstract] [Full Text] [Related]

  • 12. Peripheral SMN restoration is essential for long-term rescue of a severe spinal muscular atrophy mouse model.
    Hua Y, Sahashi K, Rigo F, Hung G, Horev G, Bennett CF, Krainer AR.
    Nature; 2011 Oct 05; 478(7367):123-6. PubMed ID: 21979052
    [Abstract] [Full Text] [Related]

  • 13. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy.
    Riessland M, Ackermann B, Förster A, Jakubik M, Hauke J, Garbes L, Fritzsche I, Mende Y, Blumcke I, Hahnen E, Wirth B.
    Hum Mol Genet; 2010 Apr 15; 19(8):1492-506. PubMed ID: 20097677
    [Abstract] [Full Text] [Related]

  • 14. New and Developing Therapies in Spinal Muscular Atrophy: From Genotype to Phenotype to Treatment and Where Do We Stand?
    Chen TH.
    Int J Mol Sci; 2020 May 07; 21(9):. PubMed ID: 32392694
    [Abstract] [Full Text] [Related]

  • 15. Plastin 3 is upregulated in iPSC-derived motoneurons from asymptomatic SMN1-deleted individuals.
    Heesen L, Peitz M, Torres-Benito L, Hölker I, Hupperich K, Dobrindt K, Jungverdorben J, Ritzenhofen S, Weykopf B, Eckert D, Hosseini-Barkooie SM, Storbeck M, Fusaki N, Lonigro R, Heller R, Kye MJ, Brüstle O, Wirth B.
    Cell Mol Life Sci; 2016 May 07; 73(10):2089-104. PubMed ID: 26573968
    [Abstract] [Full Text] [Related]

  • 16. Calcium binding is essential for plastin 3 function in Smn-deficient motoneurons.
    Lyon AN, Pineda RH, Hao le T, Kudryashova E, Kudryashov DS, Beattie CE.
    Hum Mol Genet; 2014 Apr 15; 23(8):1990-2004. PubMed ID: 24271012
    [Abstract] [Full Text] [Related]

  • 17. Modifier genes: Moving from pathogenesis to therapy.
    McCabe ERB.
    Mol Genet Metab; 2017 Sep 15; 122(1-2):1-3. PubMed ID: 28684086
    [Abstract] [Full Text] [Related]

  • 18. Transcript levels of plastin 3 and neuritin 1 modifier genes in spinal muscular atrophy siblings.
    Yener İH, Topaloglu H, Erdem-Özdamar S, Dayangac-Erden D.
    Pediatr Int; 2017 Jan 15; 59(1):53-56. PubMed ID: 27279027
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of SMN protein, transcript, and copy number in the biomarkers for spinal muscular atrophy (BforSMA) clinical study.
    Crawford TO, Paushkin SV, Kobayashi DT, Forrest SJ, Joyce CL, Finkel RS, Kaufmann P, Swoboda KJ, Tiziano D, Lomastro R, Li RH, Trachtenberg FL, Plasterer T, Chen KS, Pilot Study of Biomarkers for Spinal Muscular Atrophy Trial Group.
    PLoS One; 2012 Jan 15; 7(4):e33572. PubMed ID: 22558076
    [Abstract] [Full Text] [Related]

  • 20. Survival motor neuron affects plastin 3 protein levels leading to motor defects.
    Hao le T, Wolman M, Granato M, Beattie CE.
    J Neurosci; 2012 Apr 11; 32(15):5074-84. PubMed ID: 22496553
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.